0 13 eps expected for trovagene inc trov 2


$-0.13 EPS Expected for TrovaGene, Inc. (TROV)


March 1, 2018 – By Kurt Siggers



Investors sentiment increased to 0.85 in 2017 Q3. Its up 0.42, from 0.43 in 2017Q2. It is positive, as 10 investors sold TrovaGene, Inc. shares while 10 reduced holdings. 9 funds opened positions while 8 raised stakes. 5.05 million shares or 53.72% more from 3.29 million shares in 2017Q2 were reported.

24,226 were reported by Two Sigma Limited Liability Corp. Citadel Ltd Limited Liability Company reported 0% in TrovaGene, Inc. (NASDAQ:TROV). State Street Corp holds 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV) for 13,300 shares. Millennium Mngmt Ltd Liability reported 342,343 shares. Princeton Capital Management accumulated 17,070 shares or 0.01% of the stock. Bank & Trust Of America Corporation De holds 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV) for 6,825 shares. Vanguard Gru owns 849,429 shares for 0% of their portfolio. Berson Corrado Investment Ltd Company, a New York-based fund reported 20,000 shares. Raymond James & Associate holds 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV) for 23,000 shares. Citigroup holds 0% or 2,000 shares in its portfolio. Barclays Plc has 25,000 shares. Da Davidson And Com accumulated 159,668 shares or 0% of the stock. Jpmorgan Chase And has 0% invested in TrovaGene, Inc. (NASDAQ:TROV). Moreover, Morgan Stanley has 0% invested in TrovaGene, Inc. (NASDAQ:TROV). Cambridge Inv Advsr invested 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV).

Analysts expect TrovaGene, Inc. (NASDAQ:TROV) to report $-0.13 EPS on March, 21.They anticipate $0.18 EPS change or 58.06 % from last quarter’s $-0.31 EPS. After having $-0.12 EPS previously, TrovaGene, Inc.’s analysts see 8.33 % EPS growth. The stock increased 3.55% or $0.0108 during the last trading session, reaching $0.3151. About 514,528 shares traded. TrovaGene, Inc. (NASDAQ:TROV) has declined 83.95% since March 1, 2017 and is downtrending. It has underperformed by 100.65% the S&P500.



TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

Among 8 analysts covering TrovaGene (NASDAQ:TROV), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. TrovaGene had 18 analyst reports since August 14, 2015 according to SRatingsIntel. H.C. Wainwright initiated it with “Buy” rating and $1.0 target in Thursday, December 21 report. Maxim Group maintained the shares of TROV in report on Monday, June 12 with “Buy” rating. The company was initiated on Tuesday, September 15 by Cantor Fitzgerald. Janney Capital downgraded the shares of TROV in report on Friday, March 11 to “Neutral” rating. The stock has “Buy” rating by Maxim Group on Thursday, July 27. The rating was maintained by Maxim Group on Tuesday, June 27 with “Buy”. Cantor Fitzgerald downgraded it to “Hold” rating and $5 target in Monday, April 25 report. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 16 report. The rating was maintained by Maxim Group on Thursday, July 6 with “Buy”. Maxim Group maintained it with “Buy” rating and $4.0 target in Tuesday, August 22 report.

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics. The company has market cap of $16.63 million. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. It currently has negative earnings. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib, a development stage FLT3 inhibitor, and Velcade (bortezomib) in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer, and other liquid and solid tumor cancers.

More recent TrovaGene, Inc. (NASDAQ:TROV) news were published by: Prnewswire.com which released: “Trovagene Announces Activation of Two Additional Clinical Trial Sites to …” on February 13, 2018. Also Prnewswire.com published the news titled: “Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled …” on February 06, 2018. Prnewswire.com‘s news article titled: “Trovagene Announces Fourth Quarter and Full-Year 2017 Results” with publication date: February 26, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Back To Top